Regulatory Environment and Drug Pricing Policies: Strict regulatory environments and government influence on drug pricing, particularly in regions with nationalized healthcare or new US price-setting programs, can significantly impact AstraZeneca's profitability and R&D investment.

R&D Success and Pipeline Development: The company's continued success hinges on its ability to develop and successfully launch innovative new drugs. Failures or delays in the R&D pipeline, unfavorable clinical trial data, or safety concerns for new treatments can materially affect future revenue and require substantial investment.

Geopolitical and Economic Volatility: Global economic trends, competitive pressures, and political instability can create financial and operational challenges. Fluctuations in currency exchange rates, changes in interest rates, inflationary pressures, and evolving international trade policies also influence AstraZeneca's global profitability and operational efficiency.